<DOC>
	<DOCNO>NCT00401661</DOCNO>
	<brief_summary>Primary objective : - End-point improvement baseline Male Sexual Health Questionnaire Ejaculation domain ( MSHQ-EjD ) men low urinary tract symptom ( LUTS ) suggestive benign prostatic hyperplasia ( BPH ) treat 6 month XATRAL 10mg daily OD . Secondary objective : - MSHQ-EjD improvement visit - Improvement International Prostate Symptom Score ( IPSS ) total score , void filling subscores , nocturia bother score end-point visit - Onset action XATRAL 10mg OD - Tolerability XATRAL 10mg OD include occurrence acute urinary retention .</brief_summary>
	<brief_title>Sexuality And Management Benign Prostatic Hyperplasia With Alfuzosin</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Inclusion criterion : Patients suffer moderate severe LUTS suggestive BPH IPSS total score â‰¥ 8 Patients sexually active Exclusion criterion : Known history hepatic severe renal insufficiency , unstable angina pectoris , concomitant lifethreatening condition Previous prostate surgery , minimally invasive procedure within 6 month prior inclusion . Planned prostate biopsy , prostate surgery minimally invasive procedure whole study period Active urinary tract infection prostatitis , neuropathic bladder , diagnosed prostate cancer Treatment 5alphareductase inhibitor phytotherapy within 6 month prior inclusion , alpha1blockers within 30 day prior inclusion Patients receive treatment erectile dysfunction ( i.e . phosphodiesterase5 inhibitor ) inclusion History postural hypotension syncope Known hypersensitivity alfuzosin The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>